Zhou Jian, Liu Tang, Wang Wanchun
Department of Orthopedics, The Second Xiangya Hospital.
Department of Sports Medicine Research Center, Central South University, Changsha, Hunan, China.
Medicine (Baltimore). 2018 Nov;97(44):e13051. doi: 10.1097/MD.0000000000013051.
Matrix metalloproteinase 9 (MMP-9) is significant in the progression of osteosarcoma (OS) via increasing tumor growth, invasion and metastasis. Although previous reports indicate the prognostic value of MMP-9 in OS, there is still a great degree on inconsistency between studies. Here we report a comprehensive evaluation of the value of MMP-9 in metastasis of OS by conducting a meta-analysis of published studies.
The quantity of the studies was evaluated using the Newcastle-Ottawa quality assessment scale (NOS). Sixteen studies with a total of 816 patients with OS were examined and we calculated the pooled odds ratio (OR) with corresponding 95% confidence interval (CI) (95% CI) to evaluate that the positive expression of MMP-9 predicts neoplasm metastasis and poor survival in OS.
The results of Meta-analysis indicated that patients with positive expression of MMP-9 were significantly associated with neoplasm metastasis (OR = 4.69, 95% CI: 3.05-7.21, P <.001) and poor survival in OS with the pooled OR of 7.19 (95% CI 4.32-11.98, P <.001) when compared to their counterparts with a negative expression of MMP-9. The results of sensitivity analysis showed that the pooled OR was stable. It doesn't significantly change when a single study was removed.
The results of meta-analysis indicated that MMP-9 may be a prognostic biomarker guiding the clinical therapy for OS.
基质金属蛋白酶9(MMP - 9)通过促进肿瘤生长、侵袭和转移,在骨肉瘤(OS)进展中具有重要意义。尽管先前的报道指出了MMP - 9在骨肉瘤中的预后价值,但研究之间仍存在很大程度的不一致。在此,我们通过对已发表研究进行荟萃分析,全面评估MMP - 9在骨肉瘤转移中的价值。
使用纽卡斯尔 - 渥太华质量评估量表(NOS)评估研究质量。对16项研究共816例骨肉瘤患者进行了检查,我们计算了合并比值比(OR)及相应的95%置信区间(CI),以评估MMP - 9的阳性表达是否预示骨肉瘤的肿瘤转移和不良生存情况。
荟萃分析结果表明,与MMP - 9阴性表达的患者相比,MMP - 9阳性表达的患者与肿瘤转移显著相关(OR = 4.69,95% CI:3.05 - 7.21,P <.001),且骨肉瘤患者生存不良,合并OR为7.19(95% CI 4.32 - 11.98,P <.001)。敏感性分析结果显示合并OR值稳定。剔除单个研究时,该值无显著变化。
荟萃分析结果表明,MMP - 9可能是指导骨肉瘤临床治疗的预后生物标志物。